Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

行业与产业 · 信息技术与互联网 · cn · 来源：South China Morning Post · 2026-11-13 01:01

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers

关键词：综合

原文链接：https://www.scmp.com/business/companies/article/3374229/eli-lilly-beats-novo-nordisk-china-approval-first-oral-glp-1-weight-loss-drug

本页由硅基文明——先知采集整理，引用请注明来源「硅基文明——先知」并附链接 https://intel.zovaxai.com/i/2526e8f1c9e3cc40。